Mesa Laboratories, Inc. (MLAB)
Stock Price Chart
Key Info
| Market Cap | 1.24B |
| Revenue (ttm) | 121.34M |
| Net Income (ttm) | -2.22M |
| Shares Out | 5.10M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | 36.76 |
| Dividend | $0.64 |
| Dividend Yield | 0.26% |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $242.31 |
| Previous Close | $247.39 |
| Change ($) | -5.08 |
| Change (%) | -2.05% |
| Day's Open | 246.73 |
| Day's Range | 242.09 - 248.20 |
| Day's Volume | 29,775 |
| 52-Week Range | 181.90 - 271.46 |
More Stats
| Market Cap | 1.24B |
| Enterprise Value | 1.15B |
| Earnings Date (est) | Nov 9, 2020 |
| Ex-Dividend Date | May 28, 2020 |
| Shares Outstanding | 5.10M |
| Float | 4.79M |
| EPS (basic) | -0.5 |
| EPS (diluted) | -0.51 |
| FCF / Share | 5.84 |
| Dividend | $0.64 |
| Dividend Yield | 0.26% |
| Earnings Yield | n/a |
| FCF Yield | 2.14% |
| Payout Ratio | n/a |
| Shares Short | 384,330 |
| Short Ratio | 9.79 |
| Short % of Float | 8.71% |
| Beta | 0.38 |
| PE Ratio | n/a |
| Forward PE | 36.76 |
| P/FCF Ratio | 46.79 |
| PS Ratio | 10.19 |
| PB Ratio | 3.36 |
| Revenue | 121.34M |
| Operating Income | 4.89M |
| Net Income | -2.22M |
| Free Cash Flow | 26.43M |
| Net Cash | 89.35M |
| Net Cash / Share | 17.51 |
| Gross Margin | 60.52% |
| Operating Margin | 4.03% |
| Profit Margin | -1.80% |
| FCF Margin | 21.78% |
| ROA | 2.57% |
| ROE | -0.89% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 118 | 103 | 96.18 | 93.67 | 84.66 | 71.33 | 52.72 | 46.44 | 39.62 | 34.23 |
| Revenue Growth | 14.11% | 7.23% | 2.68% | 10.64% | 18.69% | 35.29% | 13.54% | 17.21% | 15.74% | - |
| Gross Profit | 64.93 | 60.92 | 54.62 | 53.24 | 51.41 | 43.39 | 31.69 | 28.86 | 23.51 | 19.57 |
| Operating Income | 7.98 | 10.34 | 2.15 | 16.31 | 16.32 | 15.86 | 11.79 | 13.10 | 12.48 | 9.86 |
| Net Income | 1.35 | 7.48 | -2.96 | 11.18 | 11.17 | 9.58 | 9.00 | 8.45 | 7.92 | 6.18 |
| Shares Outstanding | 4.20 | 3.84 | 3.77 | 3.68 | 3.61 | 3.52 | 3.45 | 3.36 | 3.29 | 3.23 |
| Earnings Per Share | 0.31 | 1.86 | -0.79 | 2.91 | 2.97 | 2.63 | 2.49 | 2.35 | 2.29 | 1.86 |
| EPS Growth | -83.33% | - | - | -2.02% | 12.93% | 5.62% | 5.96% | 2.62% | 23.12% | - |
| Dividend Per Share | 0.64 | 0.48 | 0.64 | 0.64 | 0.64 | 0.62 | 0.58 | 0.54 | 0.50 | 0.46 |
| Dividend Growth | 33.33% | -25% | 0% | 0% | 3.23% | 6.9% | 7.41% | 8% | 8.7% | - |
| Operating Cash Flow | 26.56 | 30.55 | 25.72 | 17.30 | 16.90 | 10.82 | 12.37 | 11.40 | 12.49 | 8.87 |
| Capital Expenditures | -1.48 | 0.96 | -1.67 | -11.61 | -7.73 | -2.83 | -1.04 | -0.91 | -0.68 | -2.65 |
| Free Cash Flow | 25.08 | 31.51 | 24.05 | 5.70 | 9.17 | 7.99 | 11.33 | 10.49 | 11.81 | 6.22 |
| Cash & Equivalents | 81.38 | 10.19 | 5.47 | 5.82 | 5.70 | 2.03 | 5.58 | 4.01 | 7.19 | 3.55 |
| Total Debt | 140 | 22.74 | 46.26 | 54.80 | 45.25 | 26.25 | 16.50 | 4.00 | - | 6.50 |
| Net Cash / Debt | -58.90 | -12.55 | -40.79 | -48.98 | -39.56 | -24.22 | -10.93 | 0.01 | 7.19 | -2.95 |
| Assets | 420 | 157 | 164 | 172 | 161 | 117 | 97.53 | 65.92 | 50.70 | 50.56 |
| Liabilities | 200 | 45.46 | 64.74 | 73.91 | 76.07 | 43.84 | 33.20 | 13.17 | 6.78 | 14.14 |
| Book Value | 220 | 111 | 99.36 | 97.82 | 84.68 | 73.48 | 64.33 | 52.75 | 43.92 | 36.42 |
Company Profile
Company Details
| Full Name | Mesa Laboratories, Inc. |
| Country | United States |
| Employees | 460 |
| CEO | Gary M. Owens |
Stock Information
| Ticker Symbol | MLAB |
| Stock Exchange | NASDAQ |
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| Unique Identifier | NASDAQ: MLAB |
Description
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company's Sterilization and Disinfection Control segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices; and offers testing services. This segment also provides chemical and cleaning indicators that are used to assess the effectiveness of sterilization and cleaning processes. Its Instruments segment offers data loggers used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air sampling; and torque testing systems used for measure bottle cap tightness. This segment's products are used in healthcare, pharmaceutical, medical device, food and beverage, industrial hygiene, and environmental air sampling industries. The company's Biopharmaceutical Development segment develops, manufactures, and commercializes automated solutions for protein analysis, which include analysis equipment, CDs, kits, and buffers; and peptide synthesizers to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. Its Continuous Monitoring segment offers systems, which are used to monitor temperature, humidity, and differential pressure for use in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was founded in 1982 and is headquartered in Lakewood, Colorado.